Goodwin’s Life Sciences team successfully advised Mariana Oncology on a major acquisition deal, in which pharmaceutical giant Novartis agrees to purchase Mariana for an upfront sum of $1 billion and contingent milestone payments of up to $750 million. The acquisition comes as a significant step for Novartis, enhancing its portfolio with Mariana Oncology’s advanced radiopharmaceutical innovations, which show promise in transforming cancer treatment through targeted peptide-based radioligand therapeutics (RLTs). RLTs have the potential to selectively target tumor cells and minimize toxicity for patients. The comprehensive and fully integrated nature of Mariana Oncology is highlighted, with mention of its team comprising global experts in the radiopharmaceutical field. The transaction’s closure is pending customary closing conditions. Goodwin’s advising team, led by Laura U. Gulick, Sam Beavers, and Kingsley Taft, included specialists spanning multiple facets of legal counsel, from intellectual property to antitrust, compensation, benefits, tax, regulatory, labor, and employment law, with additional acknowledgment to their support structure.

Life Sciences, Legal Services,Global